HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.

Abstract
Olprinone, a specific phosphodiesterase III inhibitor, and corforsin daropate, a direct adenylate cyclase activator, are now being used in critical conditions. We investigated whether their therapeutic use provides protection against septic acute lung injury (ALI) and mortality. Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in BALB/c mice. Olprinone or colforsin daropate was continuously given through an osmotic pump that was implanted into the peritoneal cavity immediately following CLP. These treatments prevented the ALI development in CLP mice, as indicated by the findings that severe hypoxemia, increased pulmonary vascular permeability, and histological lung damage were strikingly remedied. Furthermore, continued administration of olprinone or colforsin daropate suppressed apoptosis induction in septic lungs and improved the survival of CLP mice. Olprinone and corforsin daropate enhanced Akt phosphorylation in septic lungs. Wortmannin, which inhibits the Akt upstream regulator phosphatidylinositol 3-kinase, abrogated the protective effects of olprinone and corforsin daropate on sepsis-associated lung inflammation and apoptosis. In vivo transfection of cyclic AMP response element binding protein (CREB) decoy oligodeoxynucleotide failed to negate the abilities of these agents to increase Akt phosphorylation and to inhibit IκBα degradation in septic lungs. These results demonstrate for the first time that CREB-independent Akt-mediated signaling is a critical mechanism contributing to the therapeutic effects of olprinone and corforsin daropate on septic ALI. Moreover, our data also suggest that these cyclic AMP-related agents, by blocking both nuclear factor-κB activation and apoptosis induction, may represent an effective therapeutic approach to the treatment of the septic syndrome.
AuthorsHirofumi Oishi, Ken-ichi Takano, Kengo Tomita, Mariko Takebe, Hiroki Yokoo, Mitsuaki Yamazaki, Yuichi Hattori
JournalAmerican journal of physiology. Lung cellular and molecular physiology (Am J Physiol Lung Cell Mol Physiol) Vol. 303 Issue 2 Pg. L130-40 (Jul 2012) ISSN: 1522-1504 [Electronic] United States
PMID22610350 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Androstadienes
  • Creb1 protein, mouse
  • Cyclic AMP Response Element-Binding Protein
  • Cytokines
  • Enzyme Activators
  • Imidazoles
  • NF-kappa B
  • Phosphodiesterase Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyridones
  • colforsin daropate
  • Colforsin
  • olprinone
  • Proto-Oncogene Proteins c-akt
  • Wortmannin
Topics
  • Acute Lung Injury (drug therapy, microbiology, pathology)
  • Androstadienes (pharmacology)
  • Animals
  • Apoptosis (drug effects)
  • Cecum (microbiology, pathology)
  • Colforsin (analogs & derivatives, pharmacology, therapeutic use)
  • Cyclic AMP Response Element-Binding Protein (metabolism)
  • Cytokines (blood, genetics, metabolism)
  • Enzyme Activation
  • Enzyme Activators (pharmacology, therapeutic use)
  • Hypotension (microbiology)
  • Imidazoles (pharmacology, therapeutic use)
  • Ligation
  • Lung (drug effects, metabolism, pathology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NF-kappa B (metabolism)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Phosphodiesterase Inhibitors (pharmacology, therapeutic use)
  • Phosphoinositide-3 Kinase Inhibitors
  • Pneumonia (drug therapy, microbiology, pathology)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Pyridones (pharmacology, therapeutic use)
  • Shock, Septic (blood, drug therapy, microbiology)
  • Signal Transduction
  • Wortmannin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: